Champenois Karen, Bocket Laurence, Deuffic-Burban Sylvie, Cotte Laurent, André Patrice, Choisy Philippe, Yazdanpanah Yazdan
CRESGE-LEM-CNRS, Lille, France.
AIDS. 2008 May 31;22(9):1087-9. doi: 10.1097/QAD.0b013e3282ff629b.
The expected effectiveness of protease inhibitors was assessed according to the Agence Nationale de Recherches sur le SIDA (ANRS), Rega and Stanford 2007 resistance algorithms in 93 and 87 antiretroviral therapy-naive patients, respectively, infected with B and non-B subtype viruses. Either B or non-B subtypes were considered fully susceptible to protease inhibitors, except to tipranavir/ritonavir, for which the 2007 ANRS algorithm scored non-B subtypes as naturally resistant when this algorithm was extended to these subtypes.
分别根据法国国家艾滋病研究机构（ANRS）、雷加（Rega）和斯坦福2007耐药性算法，对93例感染B亚型病毒和87例感染非B亚型病毒的初治抗逆转录病毒治疗患者评估蛋白酶抑制剂的预期疗效。除替拉那韦/利托那韦外，B亚型和非B亚型均被认为对蛋白酶抑制剂完全敏感，当2007年ANRS算法扩展至非B亚型时，该算法将其判定为天然耐药。
